Search

Research recently published by MSK scientists suggests that the best way to fight dangerous bacteria may be with other bacteria.

… Tuesday, June 20, 2017 Summary People with cancer are particularly susceptible to infections because treatment often damages their immune system. Now research is suggesting that the best way to combat these dangerous infections may be with other, nonharmful bacteria. Highlights Antibiotics are an important

A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the Annals of Surgery,([i]) is the first to identify a comprehensive list of clinical factors significantly associated with referring patients with stage 1 NSCLC to SBRT.

… Tuesday, November 5, 2024 Minimally invasive surgery (MIS) and stereotactic body radiotherapy (SBRT) are both used to treat stage 1 non-small cell lung cancer (NSCLC). While MIS remains the standard of care for patients with operable disease, selecting which patients should be referred for SBRT has been

A newly identified group of immunosuppressive cells could provide insight into the effects of immunotherapy drugs.

… Tuesday, June 12, 2018 Summary MSK researchers have identified a new group of immunosuppressive cells that are affected in opposite ways by two common checkpoint inhibitors often given in combination. These cells are easily detectable in the blood and could help doctors make immunotherapy work better

A commentary by members of Memorial Sloan Kettering Cancer Center’s (MSK) Bobst International Center along with members of the Bloomberg New Economy International Cancer Coalition (the “Coalition”) calls for global collaboration to reimagine patient-centric cancer clinical trials. The piece was published in the April 19, 2022, “The Future of Cancer Research” special Focus edition of the journal Nature Medicine.

… Thursday, April 21, 2022 A commentary by members of Memorial Sloan Kettering Cancer Center’s (MSK) Bobst International Center along with members of the Bloomberg New Economy International Cancer Coalition (the “Coalition”) calls for global collaboration to reimagine patient-centric cancer clinical trials

Scott Callahan is the second Gerstner Sloan Kettering student to receive the Joanna M. Nicolay Melanoma Foundation grant, which supports exceptional melanoma research by graduate students.

… Monday, April 28, 2014 Scott Callahan, a second-year student studying in the laboratories of Lorenz Studer in the Developmental Biology Program and Richard M. White in the Cancer Biology and Genetics Program , was awarded a $10,000 melanoma research grant by the Joanna M. Nicolay Melanoma Foundation

Cancers with certain mutations are vulnerable to ferroptosis, a form of iron-dependent cell death.

… Monday, November 23, 2020 Summary Genetic mutations that give cancers a metabolic boost may also leave them vulnerable to drugs that promote a particular form of cell death, Sloan Kettering Institute researchers have found. If there is a silver lining in cancer’s chaotic biology, it’s that the same traits

Learn about some of the exciting research that MSK doctors and scientists presented at the 2025 Annual Meeting of the American Society for Radiation Oncology.

… Wednesday, October 1, 2025 Memorial Sloan Kettering Cancer Center (MSK) presented new research on a range of important topics at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO), held September 27 to October 1 in San Francisco. The presentations included two clinical trials

Get an inside look into the life of a student from the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences.

… Tuesday, November 23, 2021 As a student at the Gerstner Sloan Kettering (GSK) Graduate School of Biomedical Sciences, you will join the laboratory of one of more than 130 scientists from Memorial Sloan Kettering Cancer Center with expertise in cancer biology, genomics, immunology, structural biology,

Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.

… Wednesday, August 19, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer

Learn why MSK researchers developed MACHETE, a new CRISPR-based technique to study large-scale genetic deletions efficiently in laboratory models.

… Monday, November 7, 2022 Highlights MACHETE is a new CRISPR-based technique to study large-scale genetic deletions efficiently in laboratory models. Using MACHETE, researchers found that a prominent deletion often eliminates a cluster of interferon genes — leading to poorer outcomes in mouse models of